E-Therapeutics

Based on advances in chemical biology and network science, network pharmacology is a distinctive new approach to drug discovery. It involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins. By addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein. Network pharmacology has the potential to provide new treatments for complex diseases where conventional approaches have failed to deliver satisfactory therapies.

Type
Public
HQ
Long Hanborough, GB
Founded
2003
Size (employees)
27 (est)
E-Therapeutics was founded in 2003 and is headquartered in Long Hanborough, GB

Key People at E-Therapeutics

Malcolm Young

Malcolm Young

Chief Executive at e-Therapeutics plc
Sean Nicolson

Sean Nicolson

Executive Director
Stuart Lavin

Stuart Lavin

Clinical Operations Manager
Steve Self

Steve Self

Development Director / Consultant

E-Therapeutics Office Locations

E-Therapeutics has office in Long Hanborough
Long Hanborough, GB

E-Therapeutics Metrics

E-Therapeutics Summary

Market capitalization

£22.1 M

Closing share price

£0.0825
E-Therapeutics's current market capitalization is £22.1 M.

E-Therapeutics Market Value History

We estimate that E-Therapeutics's current employees are approximately 11% female and 89% male.

E-Therapeutics Company Life

You may also be interested in